Carcinosarcoma of the corpus uteri
disease diseaseOn this page
Also known as body of uterus carcinosarcomacarcinosarcoma of corpus utericarcinosarcoma of the uterine bodycarcinosarcoma of the uterine corpuscarcinosarcoma of the uteruscarcinosarcoma of uterine bodycarcinosarcoma of uterine corpuscarcinosarcoma of uteruscorpus uteri malignant mixed mesodermal tumorcorpus uteri malignant mixed mesodermal tumourmalignant mixed mesodermal neoplasm of the uterine bodymalignant mixed mesodermal neoplasm of the uterine corpusmalignant mixed mesodermal neoplasm of the uterusmalignant mixed mesodermal neoplasm of uterine bodymalignant mixed mesodermal neoplasm of uterine corpusmalignant mixed mesodermal neoplasm of uterusmalignant mixed mesodermal tumor of the uterine bodymalignant mixed mesodermal tumor of the uterine corpusmalignant mixed mesodermal tumor of the uterus
Summary
Carcinosarcoma of the corpus uteri (MONDO:0016259) is a disease and 33 clinical trials. Top therapeutic interventions include cabozantinib, rucaparib, and sorafenib. A subtype of uterine body mixed cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | carcinosarcoma of the corpus uteri |
| Mondo ID | MONDO:0016259 |
| Orphanet | 213610 |
| NCIT | C9180 |
| UMLS | C1704376 |
| MedGen | 316458 |
| GARD | 0012335 |
| Anatomy (UBERON) | UBERON:0009853 |
| Is cancer (heuristic) | no |
Also known as: body of uterus carcinosarcoma · carcinosarcoma of corpus uteri · carcinosarcoma of the corpus uteri · carcinosarcoma of the uterine body · carcinosarcoma of the uterine corpus · carcinosarcoma of the uterus · carcinosarcoma of uterine body · carcinosarcoma of uterine corpus · carcinosarcoma of uterus · corpus uteri malignant mixed mesodermal tumor · corpus uteri malignant mixed mesodermal tumour · malignant mixed mesodermal neoplasm of the uterine body · malignant mixed mesodermal neoplasm of the uterine corpus · malignant mixed mesodermal neoplasm of the uterus · malignant mixed mesodermal neoplasm of uterine body · malignant mixed mesodermal neoplasm of uterine corpus · malignant mixed mesodermal neoplasm of uterus · malignant mixed mesodermal tumor of the uterine body · malignant mixed mesodermal tumor of the uterine corpus · malignant mixed mesodermal tumor of the uterus (+45 more)
Data availability: 36 cell lines.
Disease family
This is a subtype of uterine body mixed cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › uterine body mixed cancer › carcinosarcoma of the corpus uteri
Related subtypes (3): uterine corpus adenosarcoma, uterine corpus adenocarcinofibroma, uterine corpus carcinofibroma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 20 |
| PHASE1 | 4 |
| Not specified | 4 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03422198 | PHASE3 | RECRUITING | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer |
| NCT05256225 | PHASE3 | RECRUITING | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma |
| NCT00954174 | PHASE3 | UNKNOWN | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
| NCT04802876 | PHASE2 | ACTIVE_NOT_RECRUITING | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors |
| NCT05147558 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma |
| NCT05619913 | PHASE2 | RECRUITING | EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma |
| NCT05902988 | PHASE1/PHASE2 | RECRUITING | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer |
| NCT00025506 | PHASE2 | COMPLETED | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus |
| NCT00075400 | PHASE2 | COMPLETED | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT00114218 | PHASE2 | COMPLETED | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT00238121 | PHASE2 | COMPLETED | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer |
| NCT00245102 | PHASE2 | COMPLETED | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma |
| NCT00390234 | PHASE2 | COMPLETED | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma |
| NCT00478426 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| NCT00659360 | PHASE2 | COMPLETED | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma |
| NCT00687687 | PHASE2 | COMPLETED | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma |
| NCT01010126 | PHASE2 | COMPLETED | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
| NCT01061606 | PHASE2 | TERMINATED | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
| NCT01168232 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT01247571 | PHASE2 | COMPLETED | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT01935934 | PHASE2 | COMPLETED | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| NCT02874430 | PHASE2 | TERMINATED | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer |
| NCT03694262 | PHASE2 | COMPLETED | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) |
| NCT04149275 | PHASE2 | WITHDRAWN | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma |
| NCT03120624 | PHASE1 | ACTIVE_NOT_RECRUITING | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT03552471 | PHASE1 | COMPLETED | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| NCT05229601 | PHASE1 | TERMINATED | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors |
| NCT04906382 | EARLY_PHASE1 | TERMINATED | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer |
| NCT05049538 | Not specified | RECRUITING | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers |
| NCT01367301 | Not specified | TERMINATED | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer |
| NCT01991808 | Not specified | COMPLETED | Suitability of DCE-MRI for Detection of Vascular Changes After VBT |
| NCT03902379 | Not specified | WITHDRAWN | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 3 |
| RUCAPARIB | 4 | 2 |
| SORAFENIB | 4 | 2 |
| TEMSIROLIMUS | 4 | 2 |
| ERIBULIN MESYLATE | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| IMATINIB | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| METFORMIN | 4 | 1 |
| MIRVETUXIMAB SORAVTANSINE | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| PERTUZUMAB | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| SODIUM PERTECHNETATE TC 99M | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| INIPARIB | 3 | 1 |
| SARACATINIB | 3 | 1 |
| SPARTALIZUMAB | 3 | 1 |
| ZENIDOLOL | 2 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4438584 | 0 | 1 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| EXELIXIS | 0 | 1 |